Skip to Content

Redhill Biopharma Ltd ADR RDHL

Morningstar Rating
$0.53 +0.02 (3.48%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

RDHL is trading at a 51% discount.
Price
$0.46
Fair Value
$1.60
Uncertainty
Extreme
1-Star Price
$1.96
5-Star Price
$8.85
Economic Moat
Kcnrs
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RDHL is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.51
Day Range
$0.500.55
52-Week Range
$0.264.92
Bid/Ask
$0.52 / $0.53
Market Cap
$15.74 Mil
Volume/Avg
501,085 / 712,344

Key Statistics

Price/Earnings (Normalized)
Price/Sales
0.04
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Growth
Total Number of Employees
113

Valuation

Metric
RDHL
Price/Earnings (Normalized)
Price/Book Value
0.60
Price/Sales
0.04
Price/Cash Flow
Price/Earnings
RDHL

Financial Strength

Metric
RDHL
Quick Ratio
0.46
Current Ratio
0.96
Interest Coverage
0.56
Quick Ratio
RDHL

Profitability

Metric
RDHL
Return on Assets (Normalized)
1.17%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
15.94%
Return on Assets
RDHL
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ZTS
Zoetis Inc Class AGvxrzlnfhhClv$77.5 Bil
MKKGY
Merck KGaA ADRYrwtpmllgXbzjlz$76.9 Bil
HLN
Haleon PLC ADRGhlmxgmTnl$38.4 Bil
TEVA
Teva Pharmaceutical Industries Ltd ADRGgrslbhGsdt$15.9 Bil
VTRS
Viatris IncNbxnwzpyHycw$14.2 Bil
RDY
Dr Reddy's Laboratories Ltd ADRSzqgyrbmjGdlr$12.3 Bil
CTLT
Catalent IncWvzjxlrSnhpsc$10.2 Bil
PRGO
Perrigo Co PLCNtttykbHvxrt$4.4 Bil
CURLF
Curaleaf Holdings IncVnlhhkzFrrbh$3.9 Bil
PBH
Prestige Consumer Healthcare IncTzgxhzzBrcswt$3.6 Bil

Sponsor Center